InsuLife
PrivateLast Round
Debt
Apr 24, 2024
Est. Valuation
$26.13M
Total Funding Raised
$3.28M
Company Overview
InsuLife operates in Healthcare & Life Sciences and is based in Oslo. Its latest recorded funding round was a Debt round in April 2024.
InsuLife is a drug discovery company developing a transdermal, needle-free insulin and GLP-1 delivery technology designed for the administration of insulin without injections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Drug Discovery
Business Model
B2B2C
Customer Profile
Revenue Share, Hardware + Subscription, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InsuLife Comparables
Compare InsuLife with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biotts | 74% | |
| Oramed Pharmaceuticals Inc. | 74% | |
| NuGen Medical Devices Inc. | 72% |
For institutional investors. Book with your work email.
InsuLife Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 24, 2024 | ||||
| Early Funding | Apr 24, 2024 | ||||
| Debt | Aug 22, 2023 | ||||
| Crowdfunding | Oct 13, 2022 | ||||
| Accelerator | Aug 25, 2020 | ||||
Grant | Jun 21, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
InsuLife Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aleap | Accelerator |
| Innovasjon Norge | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 2, 2025
Magnus Winterman appointed as new Head of Investor Relations.
- Oct 2, 2025
Developing a spray-on-skin insulin delivery system, ILS-2501.
For institutional investors. Book with your work email.
InsuLife Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about InsuLife's valuation, stock price, and market status.
Is InsuLife a public or private company?
InsuLife is a private company.
What is the current stock price of InsuLife?
InsuLife is a private company, so its shares have no public market price. Caplight tracks InsuLife's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InsuLife worth (valuation)?
InsuLife's valuation is estimated at $26.1M based on funding round data.
Can I buy InsuLife stock?
InsuLife shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InsuLife's last funding round?
InsuLife's most recent funding round was Debt on April 24, 2024.
Who are the main investors in InsuLife?
Key investors in InsuLife include Aleap, Innovasjon Norge.
Will InsuLife IPO soon?
No public IPO plans have been announced for InsuLife.
How can I track InsuLife secondary market activity?
Caplight tracks bids, offers, and trades in InsuLife's shares on secondary markets.